Production of high titer attenuated poliovirus strains on the serum-free PER.C6 registered cell culture platform for the generation of safe and affordable next generation IPV
Background As poliovirus eradication draws closer, alternative Inactivated Poliovirus Vaccines (IPV) are needed to overcome the risks associated with continued use of the Oral Poliovirus Vaccine and of neurovirulent strains used during manufacture of conventional (c) IPV. We have previously demonstr...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2015-11, Vol.33 (48), p.6611-6616 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6616 |
|---|---|
| container_issue | 48 |
| container_start_page | 6611 |
| container_title | Vaccine |
| container_volume | 33 |
| creator | Sanders, Barbara P Oakes, Isabel de los Rios van Hoek, Vladimir Liu, Ying Marissen, Wilfred Minor, Philip D Wimmer, Eckard Schuitemaker, Hanneke Custers, Jerome HHV Macadam, Andrew Cello, Jeronimo Edo-Matas, Diana |
| description | Background As poliovirus eradication draws closer, alternative Inactivated Poliovirus Vaccines (IPV) are needed to overcome the risks associated with continued use of the Oral Poliovirus Vaccine and of neurovirulent strains used during manufacture of conventional (c) IPV. We have previously demonstrated the susceptibility of the PER.C6 registered cell line to cIPV strains; here we investigated the suspension cell culture platform for growth of attenuated poliovirus strains. Methods We examined attenuated Sabin strain productivity on the PER.C6 registered cell platform compared to the conventional Vero cell platform. The suitability of the suspension cell platform for propagation of rationally-attenuated poliovirus strains (stabilized Sabin type 3 S19 derivatives and genetically attenuated and stabilized MonoCre(X) strains), was also assessed. Yields were quantified by infectious titer determination and D-antigen ELISA using either serotype-specific polyclonal rabbit sera for Sabin strains or monoclonal cIPV-strain-specific antibodies for cIPV, S19 and MonoCre(X) strains. Results PER.C6 registered cells supported the replication of Sabin strains to yields of infectious titers that were in the range of cIPV strains at 32.5 degree C. Sabin strains achieved 30-fold higher yields (p |
| doi_str_mv | 10.1016/j.vaccine.2015.10.091 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785230727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1785230727</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_17852307273</originalsourceid><addsrcrecordid>eNqVjc1KxDAUhbNQcPx5BOEu3bQm7bR11sOI7oZBxN0Q29s2Q5rU3JvBp_IZjaLg1s05cPg-jhDXSuZKqvr2kB912xqHeSFVlbZcrtSJWMiiXmZLJV_OxDnRQUpZlWq1EB_b4LvYsvEOfA-jGUZgwxhAM6OLmrGD2VvjjyZEAuKgjSNIOI8IhCFOWR8QYbvZ5esaAg6Gkp-0Fq2FNlqOAWG2mnsfJkjxrQ7oMOjfY9I9gnYd6D4BnX61CA7f-S_2uH2-FKe9toRXP30hbu43T-uHbA7-LSLxfjL09asd-kh71dxVRSmboin_gX4Cd2Vs7Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1785230727</pqid></control><display><type>article</type><title>Production of high titer attenuated poliovirus strains on the serum-free PER.C6 registered cell culture platform for the generation of safe and affordable next generation IPV</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Sanders, Barbara P ; Oakes, Isabel de los Rios ; van Hoek, Vladimir ; Liu, Ying ; Marissen, Wilfred ; Minor, Philip D ; Wimmer, Eckard ; Schuitemaker, Hanneke ; Custers, Jerome HHV ; Macadam, Andrew ; Cello, Jeronimo ; Edo-Matas, Diana</creator><creatorcontrib>Sanders, Barbara P ; Oakes, Isabel de los Rios ; van Hoek, Vladimir ; Liu, Ying ; Marissen, Wilfred ; Minor, Philip D ; Wimmer, Eckard ; Schuitemaker, Hanneke ; Custers, Jerome HHV ; Macadam, Andrew ; Cello, Jeronimo ; Edo-Matas, Diana</creatorcontrib><description>Background As poliovirus eradication draws closer, alternative Inactivated Poliovirus Vaccines (IPV) are needed to overcome the risks associated with continued use of the Oral Poliovirus Vaccine and of neurovirulent strains used during manufacture of conventional (c) IPV. We have previously demonstrated the susceptibility of the PER.C6 registered cell line to cIPV strains; here we investigated the suspension cell culture platform for growth of attenuated poliovirus strains. Methods We examined attenuated Sabin strain productivity on the PER.C6 registered cell platform compared to the conventional Vero cell platform. The suitability of the suspension cell platform for propagation of rationally-attenuated poliovirus strains (stabilized Sabin type 3 S19 derivatives and genetically attenuated and stabilized MonoCre(X) strains), was also assessed. Yields were quantified by infectious titer determination and D-antigen ELISA using either serotype-specific polyclonal rabbit sera for Sabin strains or monoclonal cIPV-strain-specific antibodies for cIPV, S19 and MonoCre(X) strains. Results PER.C6 registered cells supported the replication of Sabin strains to yields of infectious titers that were in the range of cIPV strains at 32.5 degree C. Sabin strains achieved 30-fold higher yields (p<0.0001) on the PER.C6 registered cell platform as compared to the Vero cell platform in infectious titer and D-antigen content. Furthermore, Sabin strain productivity on the PER.C6 registered cell platform was maintained at 10l scale. Yields of infectious titers of S19 and MonoCre(X) strains were 0.5-1 log10 lower than seen for cIPV strains, whereas D-antigen yield and productivities in doses/ml using rationally-attenuated strains were in line with yields reported for cIPV strains. Conclusions Sabin and rationally-attenuated polioviruses can be grown to high infectious titers and D-antigen yields. Sabin strain infection shows increased productivity on the PER.C6 registered cell platform as compared to the conventional Vero cell platform. Novel cell platforms with the potential for higher yields could contribute to increased affordability of a next generation of IPV vaccines needed for achieving and maintaining poliovirus eradication.</description><identifier>ISSN: 0264-410X</identifier><identifier>DOI: 10.1016/j.vaccine.2015.10.091</identifier><language>eng</language><subject>Enterovirus ; Picornaviridae</subject><ispartof>Vaccine, 2015-11, Vol.33 (48), p.6611-6616</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,64387</link.rule.ids></links><search><creatorcontrib>Sanders, Barbara P</creatorcontrib><creatorcontrib>Oakes, Isabel de los Rios</creatorcontrib><creatorcontrib>van Hoek, Vladimir</creatorcontrib><creatorcontrib>Liu, Ying</creatorcontrib><creatorcontrib>Marissen, Wilfred</creatorcontrib><creatorcontrib>Minor, Philip D</creatorcontrib><creatorcontrib>Wimmer, Eckard</creatorcontrib><creatorcontrib>Schuitemaker, Hanneke</creatorcontrib><creatorcontrib>Custers, Jerome HHV</creatorcontrib><creatorcontrib>Macadam, Andrew</creatorcontrib><creatorcontrib>Cello, Jeronimo</creatorcontrib><creatorcontrib>Edo-Matas, Diana</creatorcontrib><title>Production of high titer attenuated poliovirus strains on the serum-free PER.C6 registered cell culture platform for the generation of safe and affordable next generation IPV</title><title>Vaccine</title><description>Background As poliovirus eradication draws closer, alternative Inactivated Poliovirus Vaccines (IPV) are needed to overcome the risks associated with continued use of the Oral Poliovirus Vaccine and of neurovirulent strains used during manufacture of conventional (c) IPV. We have previously demonstrated the susceptibility of the PER.C6 registered cell line to cIPV strains; here we investigated the suspension cell culture platform for growth of attenuated poliovirus strains. Methods We examined attenuated Sabin strain productivity on the PER.C6 registered cell platform compared to the conventional Vero cell platform. The suitability of the suspension cell platform for propagation of rationally-attenuated poliovirus strains (stabilized Sabin type 3 S19 derivatives and genetically attenuated and stabilized MonoCre(X) strains), was also assessed. Yields were quantified by infectious titer determination and D-antigen ELISA using either serotype-specific polyclonal rabbit sera for Sabin strains or monoclonal cIPV-strain-specific antibodies for cIPV, S19 and MonoCre(X) strains. Results PER.C6 registered cells supported the replication of Sabin strains to yields of infectious titers that were in the range of cIPV strains at 32.5 degree C. Sabin strains achieved 30-fold higher yields (p<0.0001) on the PER.C6 registered cell platform as compared to the Vero cell platform in infectious titer and D-antigen content. Furthermore, Sabin strain productivity on the PER.C6 registered cell platform was maintained at 10l scale. Yields of infectious titers of S19 and MonoCre(X) strains were 0.5-1 log10 lower than seen for cIPV strains, whereas D-antigen yield and productivities in doses/ml using rationally-attenuated strains were in line with yields reported for cIPV strains. Conclusions Sabin and rationally-attenuated polioviruses can be grown to high infectious titers and D-antigen yields. Sabin strain infection shows increased productivity on the PER.C6 registered cell platform as compared to the conventional Vero cell platform. Novel cell platforms with the potential for higher yields could contribute to increased affordability of a next generation of IPV vaccines needed for achieving and maintaining poliovirus eradication.</description><subject>Enterovirus</subject><subject>Picornaviridae</subject><issn>0264-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqVjc1KxDAUhbNQcPx5BOEu3bQm7bR11sOI7oZBxN0Q29s2Q5rU3JvBp_IZjaLg1s05cPg-jhDXSuZKqvr2kB912xqHeSFVlbZcrtSJWMiiXmZLJV_OxDnRQUpZlWq1EB_b4LvYsvEOfA-jGUZgwxhAM6OLmrGD2VvjjyZEAuKgjSNIOI8IhCFOWR8QYbvZ5esaAg6Gkp-0Fq2FNlqOAWG2mnsfJkjxrQ7oMOjfY9I9gnYd6D4BnX61CA7f-S_2uH2-FKe9toRXP30hbu43T-uHbA7-LSLxfjL09asd-kh71dxVRSmboin_gX4Cd2Vs7Q</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Sanders, Barbara P</creator><creator>Oakes, Isabel de los Rios</creator><creator>van Hoek, Vladimir</creator><creator>Liu, Ying</creator><creator>Marissen, Wilfred</creator><creator>Minor, Philip D</creator><creator>Wimmer, Eckard</creator><creator>Schuitemaker, Hanneke</creator><creator>Custers, Jerome HHV</creator><creator>Macadam, Andrew</creator><creator>Cello, Jeronimo</creator><creator>Edo-Matas, Diana</creator><scope>7QO</scope><scope>7T2</scope><scope>7T5</scope><scope>7U2</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20151101</creationdate><title>Production of high titer attenuated poliovirus strains on the serum-free PER.C6 registered cell culture platform for the generation of safe and affordable next generation IPV</title><author>Sanders, Barbara P ; Oakes, Isabel de los Rios ; van Hoek, Vladimir ; Liu, Ying ; Marissen, Wilfred ; Minor, Philip D ; Wimmer, Eckard ; Schuitemaker, Hanneke ; Custers, Jerome HHV ; Macadam, Andrew ; Cello, Jeronimo ; Edo-Matas, Diana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_17852307273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Enterovirus</topic><topic>Picornaviridae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanders, Barbara P</creatorcontrib><creatorcontrib>Oakes, Isabel de los Rios</creatorcontrib><creatorcontrib>van Hoek, Vladimir</creatorcontrib><creatorcontrib>Liu, Ying</creatorcontrib><creatorcontrib>Marissen, Wilfred</creatorcontrib><creatorcontrib>Minor, Philip D</creatorcontrib><creatorcontrib>Wimmer, Eckard</creatorcontrib><creatorcontrib>Schuitemaker, Hanneke</creatorcontrib><creatorcontrib>Custers, Jerome HHV</creatorcontrib><creatorcontrib>Macadam, Andrew</creatorcontrib><creatorcontrib>Cello, Jeronimo</creatorcontrib><creatorcontrib>Edo-Matas, Diana</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanders, Barbara P</au><au>Oakes, Isabel de los Rios</au><au>van Hoek, Vladimir</au><au>Liu, Ying</au><au>Marissen, Wilfred</au><au>Minor, Philip D</au><au>Wimmer, Eckard</au><au>Schuitemaker, Hanneke</au><au>Custers, Jerome HHV</au><au>Macadam, Andrew</au><au>Cello, Jeronimo</au><au>Edo-Matas, Diana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Production of high titer attenuated poliovirus strains on the serum-free PER.C6 registered cell culture platform for the generation of safe and affordable next generation IPV</atitle><jtitle>Vaccine</jtitle><date>2015-11-01</date><risdate>2015</risdate><volume>33</volume><issue>48</issue><spage>6611</spage><epage>6616</epage><pages>6611-6616</pages><issn>0264-410X</issn><abstract>Background As poliovirus eradication draws closer, alternative Inactivated Poliovirus Vaccines (IPV) are needed to overcome the risks associated with continued use of the Oral Poliovirus Vaccine and of neurovirulent strains used during manufacture of conventional (c) IPV. We have previously demonstrated the susceptibility of the PER.C6 registered cell line to cIPV strains; here we investigated the suspension cell culture platform for growth of attenuated poliovirus strains. Methods We examined attenuated Sabin strain productivity on the PER.C6 registered cell platform compared to the conventional Vero cell platform. The suitability of the suspension cell platform for propagation of rationally-attenuated poliovirus strains (stabilized Sabin type 3 S19 derivatives and genetically attenuated and stabilized MonoCre(X) strains), was also assessed. Yields were quantified by infectious titer determination and D-antigen ELISA using either serotype-specific polyclonal rabbit sera for Sabin strains or monoclonal cIPV-strain-specific antibodies for cIPV, S19 and MonoCre(X) strains. Results PER.C6 registered cells supported the replication of Sabin strains to yields of infectious titers that were in the range of cIPV strains at 32.5 degree C. Sabin strains achieved 30-fold higher yields (p<0.0001) on the PER.C6 registered cell platform as compared to the Vero cell platform in infectious titer and D-antigen content. Furthermore, Sabin strain productivity on the PER.C6 registered cell platform was maintained at 10l scale. Yields of infectious titers of S19 and MonoCre(X) strains were 0.5-1 log10 lower than seen for cIPV strains, whereas D-antigen yield and productivities in doses/ml using rationally-attenuated strains were in line with yields reported for cIPV strains. Conclusions Sabin and rationally-attenuated polioviruses can be grown to high infectious titers and D-antigen yields. Sabin strain infection shows increased productivity on the PER.C6 registered cell platform as compared to the conventional Vero cell platform. Novel cell platforms with the potential for higher yields could contribute to increased affordability of a next generation of IPV vaccines needed for achieving and maintaining poliovirus eradication.</abstract><doi>10.1016/j.vaccine.2015.10.091</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2015-11, Vol.33 (48), p.6611-6616 |
| issn | 0264-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1785230727 |
| source | Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Enterovirus Picornaviridae |
| title | Production of high titer attenuated poliovirus strains on the serum-free PER.C6 registered cell culture platform for the generation of safe and affordable next generation IPV |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A13%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Production%20of%20high%20titer%20attenuated%20poliovirus%20strains%20on%20the%20serum-free%20PER.C6%20registered%20cell%20culture%20platform%20for%20the%20generation%20of%20safe%20and%20affordable%20next%20generation%20IPV&rft.jtitle=Vaccine&rft.au=Sanders,%20Barbara%20P&rft.date=2015-11-01&rft.volume=33&rft.issue=48&rft.spage=6611&rft.epage=6616&rft.pages=6611-6616&rft.issn=0264-410X&rft_id=info:doi/10.1016/j.vaccine.2015.10.091&rft_dat=%3Cproquest%3E1785230727%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1785230727&rft_id=info:pmid/&rfr_iscdi=true |